GlassScriptPhysician profile
Mckayla Eberhardt
NPI 1457073124
$1,374.42
in general payments reported to CMS, 2019-2025
19 companies · $476 in 2025
The $476 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $32.61 · 2023: $370 · 2024: $496 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,341.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $227.33 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $197.21 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $186.78 | 2023-2025 | |
| Astellas Pharma US INC | $118.98 | 2023-2025 | Veozah, Myrbetriq |
| Phathom Pharmaceuticals, INC. | $99.55 | 2024-2025 | Voquezna |
| Amgen INC. | $81.26 | 2024-2025 | Krystexxa, Repatha |
| Astrazeneca Pharmaceuticals LP | $72.16 | 2023-2024 | Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $54.97 | 2023-2025 | |
| Pfizer INC. | $50.49 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.89 | 2024-2025 | Xifaxan |
| Axsome Therapeutics, INC. | $41.96 | 2025 | Auvelity |
| Novo Nordisk INC | $38.28 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Organon LLC | $37.31 | 2025 | Nexplanon |
| Xeris Pharmaceuticals, INC. | $37.25 | 2023-2024 | Gvoke Hypopen |
| Acadia Pharmaceuticals INC | $20.13 | 2024 | Daybue |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vbi Vaccine (Delaware) INC. | $19.37 | 2023 | Prehevbrio |
| Dexcom, INC. | $17.39 | 2024 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $15.88 | 2022 | |
| Seqirus USA INC | $14.23 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mckayla Eberhardt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.